HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chul-Woo Kim Selected Research

ATP Translocases Mitochondrial ADP

3/2016ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells.
1/2013ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma.
7/2010Degradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells.
6/2008Over-expression of adenine nucleotide translocase 1 (ANT1) induces apoptosis and tumor regression in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chul-Woo Kim Research Topics

Disease

37Neoplasms (Cancer)
01/2022 - 10/2002
7Breast Neoplasms (Breast Cancer)
04/2014 - 04/2006
4Lymphoma (Lymphomas)
01/2020 - 09/2013
4Adenocarcinoma
12/2016 - 09/2011
4Hepatocellular Carcinoma (Hepatoma)
03/2016 - 01/2013
4Melanoma (Melanoma, Malignant)
04/2014 - 10/2002
3Cognitive Dysfunction
06/2021 - 01/2020
3Extranodal NK-T-Cell Lymphoma
01/2020 - 07/2011
3Carcinogenesis
02/2013 - 01/2008
2Inflammation (Inflammations)
07/2022 - 01/2012
2Mitochondrial Diseases (Mitochondrial Disease)
06/2021 - 01/2021
2Neuroblastoma
01/2020 - 04/2014
2Lung Neoplasms (Lung Cancer)
03/2016 - 08/2011
2Neoplasm Metastasis (Metastasis)
04/2015 - 04/2014
2Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
04/2015 - 01/2012
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/2011 - 02/2011
2T-Cell Lymphoma (Lymphoma, T Cell)
07/2011 - 07/2005
1Weight Gain
07/2022
1Dyslipidemias (Dyslipidemia)
07/2022
1Insulin Resistance
07/2022
1Neuroinflammatory Diseases
10/2020
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2020
1Cytopenia
01/2017
1Liver Diseases (Liver Disease)
01/2017
1Hypoxia (Hypoxemia)
03/2016
1Liver Neoplasms (Liver Cancer)
07/2015
1Infections
04/2015
1B-Cell Lymphoma (Lymphoma, B Cell)
12/2014
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
11/2014
1Carcinoid Tumor (Carcinoid)
04/2014
1Small Cell Carcinoma
04/2014
1Neuroendocrine Tumors (Neuroendocrine Tumor)
04/2014
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
04/2014

Drug/Important Bio-Agent (IBA)

6Small Interfering RNA (siRNA)IBA
03/2016 - 01/2008
5DNA (Deoxyribonucleic Acid)IBA
01/2022 - 07/2008
5MicroRNAs (MicroRNA)IBA
01/2020 - 07/2011
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2020 - 02/2004
4Messenger RNA (mRNA)IBA
01/2020 - 04/2003
4LigandsIBA
11/2016 - 09/2010
4ATP Translocases Mitochondrial ADPIBA
03/2016 - 06/2008
3Biomarkers (Surrogate Marker)IBA
07/2022 - 07/2008
3Mucin-1 (CA 15-3 Antigen)IBA
01/2022 - 07/2008
3DNA VaccinesIBA
01/2018 - 07/2008
3VaccinesIBA
01/2018 - 09/2011
3Proteins (Proteins, Gene)FDA Link
04/2014 - 01/2013
2Glucose (Dextrose)FDA LinkGeneric
07/2022 - 01/2020
2LipidsIBA
07/2022 - 04/2006
2Amyloid beta-PeptidesIBA
06/2021 - 10/2020
2Adenosine Triphosphate (ATP)IBA
06/2021 - 01/2008
2AntioxidantsIBA
01/2021 - 05/2018
2Peptides (Polypeptides)IBA
10/2020 - 08/2007
2Complement System Proteins (Complement)IBA
12/2016 - 08/2011
2Rituximab (Mabthera)FDA Link
12/2014 - 09/2013
2Oncogene Proteins (Oncogene Protein)IBA
11/2014 - 07/2010
2CytokinesIBA
09/2013 - 04/2008
2RNA (Ribonucleic Acid)IBA
01/2013 - 09/2010
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2013 - 07/2010
2Immunoglobulin G (IgG)IBA
01/2012 - 03/2009
2Adenine NucleotidesIBA
09/2010 - 01/2008
2ErbB Receptors (EGF Receptor)IBA
07/2010 - 07/2008
2Neoplasm Antigens (Tumor Antigens)IBA
03/2009 - 04/2005
2Cyclin D1IBA
07/2008 - 01/2008
2Transforming Growth Factor beta (TGF-beta)IBA
04/2008 - 07/2006
2Cycloheximide (Cicloheximide)IBA
07/2005 - 02/2004
1Reactive Oxygen Species (Oxygen Radicals)IBA
06/2021
1Insulin (Novolin)FDA Link
01/2021
1Cholinergic Agents (Cholinergics)IBA
01/2021
1Type I Tumor Necrosis Factor ReceptorsIBA
10/2020
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
10/2020
1Heme Oxygenase-1IBA
10/2020
1Caspase 3 (Caspase-3)IBA
10/2020
1Interleukin-1beta (Interleukin 1 beta)IBA
10/2020
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
10/2020
1JNK Mitogen-Activated Protein KinasesIBA
10/2020
1OccludinIBA
10/2020
1Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA
10/2020
1Chloroform (Trichloromethane)IBA
01/2020
1Pentacyclic TriterpenesIBA
01/2020
1ethyl acetateIBA
05/2018
1trimethyltin chlorideIBA
05/2018
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2017
1Thomsen-Friedenreich antibodiesIBA
12/2016
1PhytolIBA
07/2015
1Caspase 9IBA
07/2015
1Brentuximab VedotinIBA
06/2015
1monomethyl auristatin EIBA
06/2015
1Doxycycline (Periostat)FDA LinkGeneric
04/2015
1STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
12/2014
1Sphingosine-1-Phosphate ReceptorsIBA
12/2014
1Lysine (L-Lysine)FDA Link
11/2014
1SynteninsIBA
04/2014
1Focal Adhesion Protein-Tyrosine KinasesIBA
04/2014
1p38 Mitogen-Activated Protein KinasesIBA
04/2014
1Macrophage Colony-Stimulating FactorIBA
09/2013
1ChemokinesIBA
09/2013
1epigallocatechin gallate (epigallocatechin-3-gallate)IBA
09/2013
1Interleukin-6 (Interleukin 6)IBA
09/2013

Therapy/Procedure

8Therapeutics
11/2016 - 04/2006
4Immunotherapy
12/2016 - 04/2005
1Intradermal Injections
01/2018